WST
West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc.WST

353.71USD
-1.10%
Nov 08, 2026
WST overview ready
The chart confirms it.
This is what Trading Compass has established for West Pharmaceutical Services, Inc. so far; the remaining research is not yet available.
Theme not measured
No economic group is assigned yet.
An early price trend
Longer-term context reads early trend, with a near-term setup of daily advance.
Valuation not measured
Fundamentals not measured
Market Jul 13Filing Sep 30Price action Jul 13

Conviction Level

Theme Momentum has no canonical measurement for this company — a research-profile dimension, not an input to this score.

PriceAction7.5BusinessPerformance5.0BusinessQuality8.4Valuation—ThemeMomentum—Mixed — Revenue is still growing (+8.7% YoY), but growth has slowed for 2 consecutive quarters, down from +21%. Diluted EPS growth has strengthened to +57% year over year ($3.02), up from +18%. — From filed financial statements. Describes the recent trajectory of the business, not the stock. 20 of the 100 Conviction points.

Conviction uses Price Action, Business Performance, Business Quality, Valuation. Theme Momentum is research context, not an input.

Theme momentumPrimary theme · group context, not entry timing
No economic group yet — pending research
Price
Loading price history…

Price Action

An early price trend
Longer-term context reads early trend, with a near-term setup of daily advance.

Key Financials

Market Cap
$24.6B
Avg Volume (60D)
855.9K
60 sessions
Revenue Growth YoY
+6.3%
FY2025 vs FY2024
Gross Margin
+37.6%
Trailing twelve months
Operating Margin
+23.0%
Trailing twelve months
Free Cash Flow Yield
+1.8%
P/E
38.6x
EV / EBITDA
25.3x
EV / Sales
7.2x
Market metrics as of Jul 13, 2026
Financial results for the period ended Sep 30, 2026
Filed balance-sheet data as of Sep 30, 2026

Business Performance

Mixed

Revenue is still growing (+8.7% YoY), but growth has slowed for 2 consecutive quarters, down from +21%. Diluted EPS growth has strengthened to +57% year over year ($3.02), up from +18%.

Latest reported: Q3 FY2026, ended Sep 30
Revenue growthSlowing
+8.7%
$875M in Q3 FY2026 · YoY
YoY growth, last 4 quarters
  1. +7.5%
  2. +21%
  3. +14%
  4. +8.7%
Earnings growthAccelerating
+57%
Diluted EPS $3.02 vs $1.92 a year earlier · GAAP
Diluted EPS YoY (GAAP), last 4 quarters
  1. +2.2%
  2. +56%
  3. +18%
  4. +57%
Operating marginExpanding
30.6%
+9.8 pp YoY · gross margin 39.7% (+3.1 pp)

Business Quality

8.4 / 10

How well the business earns on its assets, converts earnings to cash and funds itself — read from its SEC filings.

Fundamentals & Valuation

No valuation has been published for this company yet.

Company Research

Research coverage for this company is in progress.

Economic classification

Loading the economic classification…

Business & Markets

No company profile has been published for this ticker yet.